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InfuShield: a shielded enclosure for administering therapeutic
radioisotope treatments using standard syringe pumps
Dominic P. Rushfortha, Brenda E. Pratta, Sarah J. Chittendena, Iain S. Murraya,
Louise Causerb, Matthew J. Graya, Jonathan I. Geara, Yong Dub
and Glenn D. Fluxa
The administration of radionuclide therapies presents
significant radiation protection challenges. The aim of this
work was to develop a delivery system for intravenous
radioisotope therapies to substantially moderate radiation
exposures to staff and operators. A novel device
(InfuShield) was designed and tested before being used
clinically. The device consists of a shielded enclosure which
contains the therapeutic activity and, through the hydraulic
action of back-to-back syringes, allows the activity to be
administered using a syringe pump external to the
enclosure. This enables full access to the pump controls
while simultaneously reducing dose to the operator. The
system is suitable for use with all commercially available
syringe pumps and does not require specific consumables,
maximising both the flexibility and economy of the system.
Dose rate measurements showed that at key stages in an
131I mIBG treatment procedure, InfuShield can reduce dose
to operators by several orders of magnitude. Tests using
typical syringes and infusion speeds show no significant
alteration in administered flow rates (maximum of 1.2%).
The InfuShield system provides a simple, safe and low cost
method of radioisotope administration. Nucl Med Commun
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Introduction
131I mIBG and 90Y/177Lu DOTATATE are routinely
administered for radioisotope therapy [1]. The adminis-
tration of such therapies presents a number of challenges:
the infusion must be given at a steady gradual rate to
minimize potential complications [2]. The operator
should be able to monitor and alter the rate of flow as the
infusion takes place. It must also be possible to stop the
infusion quickly and easily in the case of an emergency.
The equipment should contain spills and leaks to mini-
mize the risk of radioactive contamination. It must also
be easy to clean to satisfy infection control requirements
and facilitate decontamination. The equipment should
also appear professional, represent good value for money
and, ideally, be easy to store and transport. Of particular
importance, the absorbed dose to staff and the public
must be as low as reasonably practicable [3]. This tech-
nical note details a system designed to administer such
therapies while fulfilling all of these criteria.
Fig. 1
The components comprising InfuShield. From top to bottom; lids (×3),
internal syringes (×2), inserts (×2), liner, lead shielding, outer cover.
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Technical note
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Materials and methods
Construction
Designed and constructed entirely in house, the
InfuShield device was created to safely contain ther-
apeutic quantities of 131I, 90Y and 177Lu. The device
consists of multiple components (Fig. 1) that, when
assembled, surround two back-to-back syringes with
three encasing layers (Fig. 2); a core of Perspex (light
grey), a layer of lead shielding (dark grey) and an outer
shell of Perspex.
At the centre of the device, a liner box holds interchange-
able inserts into which syringes slot easily and quickly.
Inserts were created to hold 30 and 50ml syringes; inserts
for other syringe sizes could be easily fabricated. The liner is
watertight and easy to decontaminate in case of spills.
Constructed of Perspex, the liner and inserts also attenuate
the high energy electron emissions of isotopes such as 90Y
(principal β emission: 2279 keV [4]).
The lead shielding (Table 1) was designed to attenuate
the γ emissions from therapeutic quantities of 131I (prin-
cipal γ emission: 364 keV [5]) to acceptable levels. This
ensured that it would also be sufficient for 177Lu (prin-
cipal γ emission: 112 keV [6]) and any Bremsstrahlung
produced in the Perspex. The individual sections of lead
shielding interleave so that there are no direct beam paths
through the shielding. Narrow labyrinths for the intrave-
nous lines (Fig. 2) also minimize radiation leakage, while
being straight enough to allow the easy and rapid insertion
of syringes containing therapeutic levels of activity.
The Perspex outer shell covers, protects and holds in
place the interlocking lead bricks. This gives the device a
robust exterior that can be easily cleaned; satisfying both
decontamination and infection control requirements.
The lids were also constructed of three layers, consisting
of lead sandwiched between sheets of Perspex. This
combination provides shielding for β and γ radiations,
protects the soft lead from knocks and facilitates clean-
ing. The lids interleave with one another, requiring the
middle lid to be inserted last and removed first, to ensure
there are no gaps in the shielding. Strong and ergonomic
nylon handles provide secure grips for manipulating the
lids, which weigh 6 kg. This is in line with the Health
and Safety Executives general guidance [7], which
recommends a maximum load of 7 kg for items that are
lifted between mid-lower leg and shoulder height.
In total InfuShield weighs 98.6 kg. Even accounting for a
robust trolley to support it, this is well within the
guideline levels for pushing and pulling over a flat, level
surface using a well-maintained handling aid [7]. In
addition, its low centre of gravity makes the device
inherently stable during transport.
Function
In all, the device requires three identical syringes. The
syringe containing radioactivity (labelled C in Fig. 3) is
driven by a second syringe (B in Fig. 3) which is filled
hydraulically, via a flexible intravenous line, by a third
syringe (A in Fig. 3) that is in turn driven by a syringe
pump. In our centre Alaris GH syringe pumps (Alaris;
Cardinal Health, Rolle, Switzerland) are used, although
any syringe pump could be accommodated.
Following administration, saline is used to flush out any
remaining activity from the therapy syringe and intrave-
nous line. This ensures the full administration of the
prescribed activity and minimizes residual contamination.
The syringe driver is disengaged from the plunger of
syringe A and a three-way tap turned so that the contents
of the saline syringe (D in Fig. 3) can be pushed into
syringe C (simultaneously reversing syringes A and B).
The three-way tap is then returned to its original posi-
tion, the syringe driver is re-engaged with syringe A and
the pump is used to drive the flush into the patient.
Syringes A and B and the line connecting them form a
sealed hydraulic system. The system is prepared in
advance of and separately from the therapeutic admin-
istration. Saline is used as the hydraulic fluid; this is
coloured with food dye to ensure that the hydraulic
components are instantly distinguishable from patient
lines. The syringes are also labelled and syringe A is
marked to show the fluid volume that remains when
syringe C is emptied.
Interchangeable inserts permit the use of a variety of
syringe sizes and types. It is essential that syringes A and
B have the same internal cross section so that syringe C is
driven at the speed set by the pump. As the Alaris pump
automatically detects the inserted syringe type and uses
this to determine the plunger speed required, syringe A
(and therefore B) must also be identical to syringe C to
ensure that the correct rate is selected. To ensure
Fig. 2
Cross section of InfuShield showing the intravenous line labyrinths.
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compliance every insert carries a warning, stating ‘All
three syringes must be of the same size and type’.
Figure 4 shows the completed device as set up when
performing an infusion. The lids would normally be in
place during an infusion but were removed so that the
internal workings could be shown. The rear of the Alaris
pump driving InfuShield can be seen on the right of
the image.
Testing methodology
Before clinical use, tests were carried out to investigate
the effect of the device on administered flow rates and
the functioning of the occlusion alarm.
Flow rate
The InfuShield system was set up as described in the
‘Function’ section, using BD plastipak syringes (Becton
Dickinson, Franklin Lakes, New Jersey, USA), a BD
Connecta three-way tap, an Alaris GH syringe pump and
50 cm lines of 1 mm internal diameter. At the end of the
administration line, in place of the patient in Fig. 3,
a 22 G Braun winged safety intravenous catheter (Braun,
Melsungen, Germany) was attached to a clamp above a
beaker resting upon a calibrated Sartorius 1474 MP 8-2
electronic scale (Sartorius, Goettingen, Germany). The
InfuShield device was then used to drive a syringe of
water, which dripped from the catheter into the beaker. A
webcam was used to record the weight of the beaker at
60 s intervals, until the administration syringe had been
emptied and the pump stopped.
The test was carried out with both 30 and 50 ml syringes,
using three different infusion speeds (30, 60 and 90 ml/h)
that cover the range normally used for clinical adminis-
trations. For comparison each test was repeated without
using InfuShield, with the syringe pump driving the
administration syringe directly.
F-tests were carried out on the acquired measurement
data using the Excel data analysis (two sample for var-
iances) package, to determine if there were any statisti-
cally significant differences in the variances of the results










































































Photo of InfuShield, with lids removed, set up for an infusion using a
50ml syringe.
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Occlusion alarm
The Alaris GH syringe pump, in common with other
pumps, has an occlusion alarm that is triggered when the
pressure exerted by the pump exceeds a set limit. The
purpose of the alarm is to warn the user that the line is
blocked and to stop an excess of pressure building up in
the line. Once an occlusion occurs it takes time for the
pressure to reach the level required to trigger the alarm. A
test was devised to determine what effect InfuShield
would have on the alarm.
Using the same apparatus as used to test flow rate, the
pump was set to a rate of 90 ml/h and allowed to run until
a continuous flow was passing through the entire appa-
ratus. The three-way tap was then closed and a stopwatch
timer simultaneously started. The timer was halted as
soon as the occlusion alarm sounded. The measurement
was repeated 30 times, both with and without the
InfuShield device in place.
Shielding
Dose rate measurements were acquired to confirm that
the shielding functioned as designed. A 5.8 GBq NaI
capsule was placed in the position of the active syringe
and measurements were taken from a variety of positions
at a distance of 50 cm; this being the approximate dis-
tance between the shielding and the torso of an indivi-
dual pushing the trolley. For comparison dose rate
measurements were also made of the capsule when
unshielded and when contained within a typical syringe
box. Results were adjusted to give dose rates for a typical
administered activity of 7.4 GBq (assuming a normal
activity range of 3.7–11.2 GBq [2]). The same metho-
dology was used to make dose rate measurements with
therapeutic 90Y administration syringes in place within
the system.
Staff doses
To determine the staff doses received during adminis-
trations, the Clinical Nurse Specialist (CNS) performing
the procedure routinely wore an Electronic Personal
Dosimeter during the treatments.
Results
Flow rate
Figure 5 shows the average flow rates recorded for each
of the set ups, along with the SDs of the results. Table 2
shows the same results along with the results of the sta-
tistical analysis.
Measured flows showed a high level of consistency with
the set flow rates, both when the syringes were directly
driven by the pumps and when driven using InfuShield.
The largest measured average difference in flow rate
resulting from the addition of the InfuShield device
was 1.21%.
For all combinations of syringe size and pump speed, the
variance in readings increased when InfuShield was used.
The results of the F-tests show that these increases are
statistically significant for those readings carried out at 30
and 60ml/h. The largest increase in variance was for 50ml
syringes being driven at 60ml/h, where the coefficient of
variation was more than double, from 1.31 to 2.99%.
Occlusion alarm
Figure 6 shows the results of the occlusion alarm test. On
average the use of InfuShield increases the time to alarm
from 14.6 to 22.3 s.
Shielding
The dose rate measurements carried out with 131I are
shown in Table 3. Maximum dose rates 50 cm from
InfuShield (horizontally) are 1081 times less than for an
unshielded source of the same activity and 293 times less
than for the same activity contained within a syringe box.
Dose rate measurements (and even count rate measure-
ments using mini Geiger monitors) with 90Y were too low
to be distinguished from background.
Staff doses
Nine Electronic Personal Dosimeter staff doses were recor-
ded for the CNS during the administration of 131I mIBG
treatments (activity range: 4.5–22.3GBq) using InfuShield.
These showed a mean±SD dose of 58.8±43 µSv per treat-
ment with a range of 18–141 µSv. There was no significant
correlation between the activities administered and the doses
Fig. 5
Flow rates recorded with the syringe directly driven by the pump and by
InfuShield using 30 and 50ml syringes. Readings were performed with
the pump set to 30, 60 and 90ml/h. Error bars show the SD of
measurements taken at 1 min intervals.
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received by the CNS, r=0.46, P=0.21. Mean dose per unit
absorbed activity was 6.7±6.2 µSv/GBq.
Discussion
The number and range of radionuclide therapies con-
tinue to expand with the clinical introduction of new
radiotherapeutics. There is also increasing evidence that
because of the range of absorbed doses delivered from
fixed activities, personalisation of treatment may entail the
administration of higher activities than have previously
been given [8]. With this in mind, limiting staff exposure
during administrations is of increasing importance.
Various methods are employed to administer radio-
pharmaceuticals. One example dispenses 131I mIBG
directly from the vials in which it is delivered by a burette
to allow dilution. This eliminates the need for radio-
pharmacy to prepare a syringe, reducing dose to radio-
pharmacy staff. However, this system is large, making it
inconvenient to store and transport. It is complex,
requiring additional training for staff, is designed for use
with only one radioisotope and requires proprietary dis-
pensing kits for every use that add significant cost and
make the system unusable in the case of a supply shortage.
Treatments can also be delivered using a syringe pump
enclosed within a lead brick castle. This cost effective
solution uses standard equipment. However, to see the
pump controls and infusion progress, shielding must be
removed, exposing the operators. Because of the proxi-
mity of the activity to the pump controls, even greater
operator (particularly finger) dose is incurred when set-
ting up and adjusting the infusion. Pump design (e.g. if it
is front loading) may make it difficult to encase, whereas
the size and weight of the shielding needed may present
hazards, particularly with transportation.
The InfuShield system is relatively compact and easy to
transport. The use of standard equipment means staff are
familiar with the components and costs are minimized.
The segregation of shielding and pump allows for the use
of any pump, whatever its design and dimensions. It also
grants the user full access to the pump and its controls so
that the infusion can be monitored and adjusted, while
simultaneously providing a high level of shielding.
Flow rate
The tests carried out show that InfuShield has little
effect on the flow rate. The small differences noted show
no distinct pattern, being evenly split between increasing
and decreasing the flow. Even the largest difference
(1.29%) in flow rate compares favourably to the system
Table 2 Results from flow rate measurements
Infusion speed (ml/h) 30 60 90
Syringe size (ml) 30 50 30 50 30 50
Infushield in line Without With Without With Without With Without With Without With Without With
Number of readings 58 51 112 91 30 24 55 48 20 15 38 33
Mean speed (ml/h) 29.62 29.26 29.47 29.85 59.72 59.72 59.40 60.21 89.92 89.58 89.84 89.70
Difference in speed (%) –1.23 1.29 0.01 1.36 –0.38 –0.16
Coefficient of variation (%) 1.18 2.23 1.54 1.94 0.87 1.51 1.31 2.99 0.99 0.95 1.67 2.19
Difference in CoV (%) 89.38 26.11 73.19 129.19 –4.28 31.48
F>F Critical True True True True False False
P value 3.81E–06 7.13E–03 2.88E–03 4.55E–09 NA NA
NA, Not applicable.
Fig. 6
Dotplots of time taken to trigger the alarm after an occlusion, with and
without InfuShield, superimposed over box plots of the same data.
Table 3 Dose rates from 7.4 GBq of 131I
Positions Doses (µSv/h)
50 cm from end containing activity 1.1
50 cm from end opposite activity 0.6
50 cm from the sides 1.6
50 cm above the top 13.9
50 cm below the bottom 38
50 cm from source in syringe box 469
50 cm from unshielded source 1730
270 Nuclear Medicine Communications 2017, Vol 38 No 3
accuracy of ± 2% typically by volume, specified in the
pump manual [9].
Testing did show an increase in the variance of the flow
rate over the course of the infusions. However, even the
largest measured variance (2.99%) is only slightly larger
than the system accuracy and was considered insignif-
icant by our clinical staff.
Occlusion alarm
The testing showed that occlusion alarms are delayed by
the use of InfuShield. It is believed that this is due to the
increased volume in the system and the compressible
bungs inside the two additional syringes. The clinical team
considered the time to alarm of no clinical significance, so
long as the maximum pressure could not exceed the limit
set on the pump. The occlusion test demonstrated that
despite a longer build-up, the alarm still functioned cor-
rectly once the maximum pressure had been reached.
Shielding
The results of the 131I dose rate measurements are in
good agreement with the theoretical attenuation levels
calculated. The largest difference was for the dose rate
measured through the side walls, where the dose mea-
sured was double the predicted dose. This is likely to be
due to photons scattered from the top and bottom of the
container.
A direct comparison of the effectiveness of InfuShield’s
shielding with that of other administration systems was
not possible because of a lack of published data; never-
theless, results do show that doses incurred when trans-
porting, setting up, viewing and adjusting an 131I infusion
are 1000 times lower using InfuShield than they would
be if the therapeutic activities were driven directly by an
unshielded pump. InfuShield also increases the distance
from the activity to the pump’s controls by ~ 10-fold.
Therefore, finger doses from accessing those controls are
100 000 times smaller. The measurements made with 90Y
and the calculated attenuation of 177Lu (Table 1) show
that with therapeutic quantities of these isotopes, dose
rates will be reduced to negligible levels.
InfuShield was designed to reduce staff doses as much as
practicable while taking into account health and safety
considerations. However, the thickness of the shielding
was determined by the high energy γ emissions of 131I.
Much less lead would be required if only 90Y or 177Lu was
to be used. This would considerably reduce the weight of
the device and the associated health and safety risks. In
the case of 177Lu, 0.7 mm of lead would reduce the dose
by a factor of 1000, resulting in a dose of 0.03 µSv/h,
50 cm from a 3700MBq source (Rad Pro Calculator,
version 3.26; Ray McGinnis; http://www.radprocalculator.
com). This should also provide adequate shielding for
90Y, as the inner layer of Perspex will effectively stop the
β emissions (10.3 mm range in Perspex) resulting in a
Bremsstrahlung spectrum, the majority of which will be
attenuated by the lead [10].
Staff doses
Good practice when implementing a new radiation proce-
dure is to set a staff dose constraint equal to the public dose
constraint of 300 µSv/year [3]. At our institution we carry
out an average of six 131I mIBG administrations per year,
with staff typically spending less than an hour, per
administration, in close proximity to InfuShield. Using the
reported dose rates we calculate that annual staff doses
from InfuShield, for this procedure, are less than 10 µSv.
Measured doses, however, show that administering staff
receive 353±144 µSv annually (six procedures). The addi-
tional dose measured is principally because of radiation
emanating from the patient. The large range in the doses
received and their poor correlation with the administered
activity result from variations in the level of nursing care
required by the (mainly paediatric) patients. Despite this,
received doses compare well with other published data
[11]. Further optimisation should focus on reducing staff
doses received from patients. Doses to radiopharmacy staff
[12] might also be reduced through the use of automated
dispensing systems.
Clinical use
The InfuShield device was approved for use by our
medical devices department and lead infection preven-
tion nurse as well as the relevant nuclear medicine con-
sultants and nursing staff. A standard operating procedure
was developed and the device has now been used to
deliver over 200 131I mIBG and 90Y DOTATATE
therapies. It has not been used to deliver any 177Lu
therapies as our department does not presently carry out
this treatment.
Conclusion
The InfuShield system enables therapeutic radionuclide
therapies to be administered from a fully shielded syringe
using any commercially available syringe driver and
intravenous line configuration. The separation of the
pump from the radioactive therapeutic agent allows for
effective shielding while simultaneously allowing easy
access to the pump controls and a clear view of the pump,
its display and the progress of the infusion. The dose
rates measured with 131I and 90Y show it to be suitable for
a wide range of isotopes including 177Lu.
The system helps to achieve as low as reasonably prac-
ticable absorbed staff doses, during radionuclide therapy
treatments that are functionally equivalent to routine,
syringe pump driven, infusions. InfuShield is a simple
and safe radioisotope infusion solution.
Acknowledgements
This work was supported by NHS funding to the NIHR
Biomedical Research Centre at The Royal Marsden
InfuShield radioisotope infusion system Rushforth et al. 271
Hospital NHS Foundation Trust and The Institute of
Cancer Research.
The authors would also like to thank Clive Long and
Nick Smith of the radiotherapy workshop for all their
help and assistance.
Conflicts of interest
There are no conflicts of interest.
References
1 Rojas B, Hooker C, McGowan DR, Guy MJ. Five years of molecular
radiotherapy growth in the UK: survey results from 2007 to 2012. Nucl Med
Commun 2015; 36:761–465.
2 Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure
guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl
Med Mol Imaging 2008; 35:1039–1047.
3 Health and Safety. The Ionising Radiations Regulations 1999 Statutory
Instrument No 3232. London: HMSO; 1999.
4 Bé M, Chistè V, Dulieu C, Browne E, Baglin C, Chechev V, et al.
Monographie BIPM-5 – table of radionuclides, volume 3. Sévres, France:
Bereau International des Poids et Mesures; 2006.
5 Bé M, Chistè V, Dulieu C, Browne E, Chechev V, Kuzmenko N, et al.
Monographie BIPM-5 – table of radionuclides, volume 1. Sévres, France:
Bereau International des Poids et Mesures; 2004.
6 Bé M, Chistè V, Dulieu C, Browne E, Chechev V, Kuzmenko N, et al.
Monographie BIPM-5 – table of radionuclides, volume 2. Sévres, France:
Bereau International des Poids et Mesures; 2004.
7 Health and Safety Executive. Manual handling at work – a brief guide.
London: Health and Safety Executive.
8 Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D,
et al. Dosimetry for fractionated (131)I-mIBG therapies in patients with
primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother
Radiopharm 2007; 22:105–12.
9 Alaris Medical Systems. Alaris GH Syringe pump – directions for use EN
(1000DF00328, Issue 4). Rolle, Switzerland: Carefusion; 2015. Available
at: https://www.carefusion.co.uk/Documents/international/guides/directions-
for-use/infusion/1000DF00328.pdf.
10 Jødal L. Beta emitters and radiation protection. Acta Oncol (Madr) 2009;
48:308–13.
11 Turpin BK, Morris VR, Lemen L, Weiss BD, Gelfand MJ. Minimizing nuclear
medicine technologist radiation exposure during 131I-MIBG therapy. Health
Phys 2013; 104 (2S):S43–S46.
12 Pant GS, Sharma SK, Rath GK. Finger doses for staff handling
radiopharmaceuticals in nuclear medicine. J Nucl Med Technol 2006;
34:169–173.
272 Nuclear Medicine Communications 2017, Vol 38 No 3
